EyePoint, Inc. has completed enrollment of over 480 patients in its two Phase 3 clinical trials, COMO and CAPRI, testing DURAVYU™ for diabetic macular edema (DME). The trials enrolled participants ahead of schedule, demonstrating strong interest from specialists and patients. DURAVYU is a sustained-delivery treatment designed to reduce injection frequency and target multiple disease pathways. Topline data from these trials are expected in the fourth quarter of 2027, potentially offering a more durable treatment option for DME, a leading cause of vision loss in diabetics.
Bitcoin surged above $81,700 and Ethereum topped $2,600 following the Federal Reserve's unanimous 25 basis point rate hike, the first since 2023, signaling an end to the rate cut/pause cycle. The rally was further fueled by fresh regulatory moves: th...
On September 19, a hacker exploited vulnerabilities to drain about 8.7 million FET tokens worth $1.53 million from Fetch.ai and illicitly minted roughly 408.5 million NTX tokens valued at $462,730 through NuNet. The total affected assets amount to ap...
On September 18, 2026, U.S. spot Bitcoin ETFs recorded net inflows of $433.03 million, marking the second consecutive day of positive flows. Fidelity's Wise Origin Bitcoin Fund (FBTC) led with $310.72 million in net inflows, followed by BlackRock's i...
Google and Meta have launched competing AI agents, with Google's CC targeting family productivity and Meta's Muse focusing on personal digital autonomy. For retirement investors, Google's stock is more attractive due to its lower valuation multiples,...
The Federal Reserve increased its benchmark interest rate by 25 basis points to 3.75%-4.00%, marking the first hike in three years and signaling potential further increases before year-end. U.S. stock markets showed mixed results with the Dow down 1....
